Form SC 13G/A NxStage Medical, Inc. Filed by: VANGUARD GROUP INC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
Selloff in NxStage Medical (NXTM) Seems 'Excessive'; BTIG Reaffirms at 'Buy'
February 11, 2016 9:48 AM ESTBTIG is out in defense of NxStage Medical, Inc. (NXTM) following the company's Q4, FY16 results reported on Wednesday. The firm rates NxStage at Buy with a price target of $27.
Analyst Sean Lavin noted that NxStage posted FY16 revenue of $336 million, which exceeded the company's outlook of $332 - $333 million. But, a... More
